ACS infectious diseases · 2025
Mycobacterium tuberculosis Sulfate Ester Dioxygenase Rv3406 Is Able to Inactivate the RCB18350 Compound.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Recchia Deborah, Stelitano Giovanni, Egorova Anna, Batisti Biffignandi Gherard, Savková Karin, Kafková Radka, Huszár Stanislav, Marino Cerrato Antonio, Slayden Richard A, Cummings Jason E, Whittel Nicholas, Bauman Allison A, Robertson Gregory T, Rank Laura, Urbina Fabio, Lane Thomas R, Ekins Sean, Riabova Olga, Kazakova Elena, Mikušová Katarína, Sassera Davide, Degiacomi Giulia, Chiarelli Laurent Robert, Makarov Vadim, Pasca Maria Rosalia
Аннотация
Among the critical priority pathogens listed by the World Health Organization, Mycobacterium tuberculosis strains resistant to rifampicin present a significant global threat. Consequently, the study of the mechanisms of resistance to new antitubercular drugs and the discovery of new effective molecules are two crucial points in tuberculosis drug discovery. In this study, we discovered a compound named RCB18350, which is active against M. tuberculosis growth and exhibits a minimum inhibitory concentration (MIC) of 1.25 μg/mL. It was also effective against multidrug-resistant isolates. We deeply studied the mechanism of resistance/action of RCB18350 by using several approaches. We found that Rv3406, an iron- and α-ketoglutarate-dependent sulfate ester dioxygenase, is capable of metabolizing the compound into its inactive metabolite. This finding highlights the role of this enzyme in the mechanism of resistance to RCB18350.